Skip to content
    Font Size

    IV Antibiotics Could Help Treat Skin Infections

    Study found two drugs worked as well as standard medication, with far fewer infusions needed

    WebMD News from HealthDay

    By Amy Norton

    HealthDay Reporter

    WEDNESDAY, June 4, 2014 (HealthDay News) -- Severe skin infections are often treated with IV antibiotics for days. But two new drugs -- given once a week, or just once -- could offer an alternative, researchers report.

    The findings come from two independent studies published June 5 in the New England Journal of Medicine. In one, researchers found that a single-dose IV antibiotic called oritavancin worked as well as standard antibiotic treatment among 954 patients with serious skin infections.

    In the other trial, involving more than 1,300 patients, researchers tested an IV antibiotic called dalbavancin, which was given once a week for two weeks. Again, it was as effective as the standard first-choice treatment.

    That standard is the long-used antibiotic vancomycin, which has to be infused twice a day, for up to 10 days. And that can mean an extended stay in the hospital.

    One infectious disease expert said the new drugs could "revolutionize" the treatment of serious skin infections, by avoiding prolonged treatment.

    "They're easy to use," said Dr. Henry Chambers, a professor of medicine at the University of California, San Francisco. "And easy is better than hard, all things being equal."

    Dr. G. Ralph Corey, the lead researcher on the oritavancin trial, agreed.

    "It's simple and it works," said Corey, a professor of medicine and infectious diseases at Duke University in Durham, N.C.

    Some patients might be able to receive an infusion of the drug and then go home, according to Corey. "With others you may need to watch them for 12 to 24 hours, to see how they do," he said.

    "Oritavancin kills [bacteria] very rapidly, so clinicians can note a response within 24 hours," Corey said.

    Oritavancin is not yet on the market, but dalbavancin is. The U.S. Food and Drug Administration approved dalbavancin on May 23, under the brand name Dalvance. So far, it is cleared only for treating bacterial infections of the skin and underlying tissue.

    Many of those infections are caused by methicillin-resistant Staphylococcus aureus bacteria. That strain, often called MRSA, is considered a "superbug" because it is resistant to many existing antibiotics. Vancomycin has long been the go-to treatment for MRSA infections.

    1 | 2 | 3

    WebMD Video: Now Playing

    Click here to wach video: Dirty Truth About Hand Washing

    Which sex is the worst about washing up? Why is it so important? We’ve got the dirty truth on how and when to wash your hands.

    Click here to watch video: Dirty Truth About Hand Washing